ChromaDex prepares to report quarterly earnings with analysts expecting break-even results

benzinga.com October 30, 2024, 10:01 PM UTC

ChromaDex is set to announce its quarterly earnings on October 31, 2024. Analysts expect the company to report an earnings per share (EPS) of $0.00. Last quarter, ChromaDex beat estimates by $0.02, resulting in a 9.51% share price increase. Analysts rate ChromaDex as a "Buy," with a one-year price target of $6.00, suggesting a potential upside of 65.75%. In comparison, peers Codexis, Lifecore Biomedical, and Personalis have higher price targets, indicating stronger expected growth. ChromaDex leads its peers in revenue growth at 11.89% and gross profit margin, but has the lowest return on equity. The company focuses on healthy aging and is known for its NAD+ precursor, Niagen.


With a significance score of 3.4, this news ranks in the top 38% of today's 19023 analyzed articles.

Get summaries of news with significance over 5.5 (usually ~10 stories per week). Read by 8000 minimalists.